Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Sarcoma

Glycogen dependent kinase 3
(GSK3)

Zebrafish and cell culture studies suggest GSK3 inhibition could help treat embryonal rhabdomyosarcoma (ERMS). In human ERMS cells, GSK3 inhibitors identified from a screen of about 40,000 compounds decreased growth compared with vehicle. In zebrafish with ERMS tumors, a GSK3 inhibitor suppressed tumor growth, depleted tumor-propagating cells and prevented tumor cell self-renewal, whereas vehicle did not. Next steps could include testing GSK3 inhibitors in mouse models of ERMS.

SciBX 7(16); doi:10.1038/scibx.2014.458
Published online April 24, 2014

Patent and licensing status unavailable

Chen, E.Y. et al. Proc. Natl. Acad. Sci. USA; published online March 24, 2014;
doi:10.1073/pnas.1317731111
Contact: David M. Langenau, Massachusetts General Hospital, Boston, Mass.
e-mail:

dlangenau@mgh.harvard.edu
Contact: Xu Wu, Harvard Stem Cell Institute, Cambridge, Mass.
e-mail:

xwu@cbrc2.mgh.harvard.edu